Download

Full Text

• Rogers L, Barani I, Chamberlain M, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. a RANO review. J Neurosurg. 2015; 122(1):4-23. doi:10.3171/2014.7. JNS131644
• Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro Oncol. 2018; 20(suppl 4):iv1-iv86. doi:10.1093/neuonc/noy131
• Agopiantz M, Carnot M, Denis C, Martin E, Gauchotte G. Hormone receptor expression in meningiomas: a systematic review. Cancers (Basel). 2023; 15(3):980. doi:10.3390/cancers15030980
• Weill A, Nguyen P, Labidi M, et al. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. BMJ. 2021; 372:n37. doi:10.1136/bmj.n37
• Reuter G, Potorac I, de Herdt C, et al. Recommendations on the management of meningioma and sex hormone therapy: the results of a collaborative effort between neurosurgical, endocrine and gynecological societies. Brain Spine. 2024; 5:104154. doi:10.1016/j.bas.2024.104154
• Hoisnard L, Laanani M, Passeri T, et al. Risk of intracranial meningioma with three potent progestogens: a population-based case-control study. Eur J Neurol. 2022; 29(9):2801-2809. doi:10. 1111/ene.15423
• Roland N; Neumann A, Hoisnard, L; Zureik, M; Weill, A. Utilisation de progestatifs et risque de méningiome intracrânien:une étude cas-témoins à partir des données du système national des données de santé (SNDS). J Epidemiol Popul Health. 2023; 72(supp 1):202290. doi:10.1016/j.jeph.2024. 202290
• Roland N, Kolla E, Baricault B, et al. Oral contraceptives with progestogens desogestrel or levonorgestrel and risk of intracranial meningioma: national case-control study. BMJ. 2025; 389:e083981. doi:10.1136/bmj-2024-083981
• Roland N, Nguyen P, Neumann A, et al. Prolonged use of chlormadinone acetate and risk of intracranial meningioma: a population-based cohort study. Eur J Neurol. 2025; 32(1):e16505. doi: 10.1111/ene.16505
• Nguyen P, Roland N, Neumann A, et al. Prolonged use of nomegestrol acetate and risk of intracranial meningioma: a population-based cohort study. Lancet Reg Health Eur. 2024; 42: 100928. doi:10.1016/j.lanepe.2024.100928
• Graillon T, Boissonneau S, Appay R, et al. Meningiomas in patients with long-term exposition to progestins: characteristics and outcome. Neurochirurgie. 2021; 67(6):556-563. doi:10.1016/j. neuchi.2021.04.018
• Kerschbaumer J, Freyschlag CF, Stockhammer G, et al. Hormone-dependent shrinkage of a sphenoid wing meningioma after pregnancy: case report. J Neurosurg. 2016; 124(1):137-140. doi:10. 3171/2014.12.JNS142112
• Passeri T, Champagne PO, Bernat AL, et al. Spontaneous regression of meningiomas after interruption of nomegestrol acetate: a series of three patients. Acta Neurochir (Wien). 2019; 161(4): 761-765. doi:10.1007/s00701-019-03848-x
• Xiao T, Kumar P, Lobbous M, et al. Depot medroxyprogesterone acetate and risk of meningioma in the US. JAMA Neurol. Published online September 2, 2025. doi:10.1001/jamaneurol.2025. 3011
• Griffin RL. The association between medroxyprogesterone acetate exposure and meningioma. Cancers (Basel). 2024; 16(19):3362. doi:10.3390/cancers16193362
• Jackson J. Black population grows to 47.9 million, 14.4%of US population. Accessed August 6, 2025. https://aurn.com/pew-research-blackpopulation-grows-to-47-9-million-14-4-of-u-spopulation/
• Montaigne I. Discrimination positive: l'urgence d'un nouveau modèle. Institut Montaigne; 2004.
• US Centers for Disease Control and Prevention. Adult obesity prevalence maps. Accessed August 6, 2025. https://www.cdc.gov/obesity/data-andstatistics/adult-obesity-prevalence-maps.html
• Fontbonne A, Currie A, Tounian P, et al. Prevalence of overweight and obesity in France: the 2020 Obepi-Roche Study by the "Ligue Contre l'Obésité". J Clin Med. 2023; 12(3):925. doi:10.3390/jcm12030925